Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a clinical study titled ‘A ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a study titled ‘Prospective ...

Vendanta's CEO also announced the company is cutting 20% of its workforce as a result of the Phase II UC trial failure.

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of ...

AbbVie’s psoriasis drug risankizumab has posted strong results in its latest phase 3 trial, as the company prepares to file the drug with global regulators.

Skyrizi (risankizumab) was previously already cleared by the FDA for adults with moderately to severely active Crohn's disease, active psoriatic arthritis, and moderate to severe plaque psoriasis.

In addition to Cantor Fitzgerald, AbbVie also received a Buy from Piper Sandler’s David Amsellem in a report issued yesterday. However, on August 4, Bernstein maintained a Hold rating on AbbVie (NYSE: ...

Patients with psoriasis who show an early response to the biologics risankizumab or guselkumab are more likely to have a long ...